{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:58:48Z","timestamp":1783479528942,"version":"3.55.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Jiao Tong University, a grantee of the Bill and Melinda Gates Foundation","award":["Global Health Grant No. OPP1070754"],"award-info":[{"award-number":["Global Health Grant No. OPP1070754"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0215607","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T20:04:36Z","timestamp":1557518676000},"page":"e0215607","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-7306","authenticated-orcid":true,"given":"Daniel L.","family":"Clemens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-281X","authenticated-orcid":true,"given":"Aleidy","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Jane","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Masle\u0161a-Gali\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-3499","authenticated-orcid":true,"given":"Xianting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-5446","authenticated-orcid":true,"given":"Chih-Ming","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (2018) Global tuberculosis report 2018. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwwhoint\/tb\/publications\/global_report\/en\/\" xlink:type=\"simple\">http:\/\/wwwwhoint\/tb\/publications\/global_report\/en\/<\/ext-link>."},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"D Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"EW Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"E2172","DOI":"10.1073\/pnas.1600812113","article-title":"Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model","volume":"113","author":"A Silva","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"14183","DOI":"10.1038\/ncomms14183","article-title":"Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time","volume":"8","author":"B-Y Lee","year":"2017","journal-title":"Nat Commun"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform","volume":"8","author":"A Zarrinpar","year":"2016","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e0207469","DOI":"10.1371\/journal.pone.0207469","article-title":"Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility","volume":"13","author":"B-Y Lee","year":"2018","journal-title":"PLoS ONE"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1365-2958.2008.06214.x","article-title":"The metabolic activity of <italic>Mycobacterium tuberculosis<\/italic>, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages","volume":"68","author":"BY Lee","year":"2008","journal-title":"Mol Microbiol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1752-0509-5-88","article-title":"Systematic quantitative characterization of cellular responses induced by multiple signals","volume":"5","author":"I Al-Shyoukh","year":"2011","journal-title":"BMC Syst Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Z Ma","year":"2010","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"IM Rosenthal","year":"2007","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.200807-1029OC","article-title":"Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?","volume":"178","author":"IM Rosenthal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"JH Grosset","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"S Tyagi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00451-06","article-title":"Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis","volume":"50","author":"E Nuermberger","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.00074-08","article-title":"Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"52","author":"E Nuermberger","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref17","first-page":"e00913","article-title":"Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"61","author":"SY Li","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1128\/AAC.47.8.2442-2444.2003","article-title":"Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis","volume":"47","author":"MH Cynamon","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201103-0397OC","article-title":"Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection","volume":"184","author":"T Zhang","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"R Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"M Protopopova","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"M Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/jm060957y","article-title":"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles","volume":"49","author":"H Sasaki","year":"2006","journal-title":"J Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1038\/s41598-017-09177-2","article-title":"NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans","volume":"7","author":"M Gengenbacher","year":"2017","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the <italic>Mycobacterium tuberculosis<\/italic> beta-lactamase by clavulanate","volume":"46","author":"JE Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.01035-15","article-title":"In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant <italic>Mycobacterium tuberculosis<\/italic> isolates","volume":"60","author":"D Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1086\/513945","article-title":"Activity of amoxicillin\/clavulanate in patients with tuberculosis","volume":"26","author":"HF Chambers","year":"1998","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/00365540152029954","article-title":"Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis","volume":"33","author":"PR Donald","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1378\/chest.99.4.1025","article-title":"Amoxicillin-clavulanic acid for treating drug-resistant <italic>Mycobacterium tuberculosis<\/italic>","volume":"99","author":"JP Nadler","year":"1991","journal-title":"Chest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nm.2120","article-title":"The <italic>Mycobacterium tuberculosis<\/italic> protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin","volume":"16","author":"R Gupta","year":"2010","journal-title":"Nat Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1128\/AAC.00023-13","article-title":"In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing\/nonreplicating <italic>Mycobacterium tuberculosis<\/italic>","volume":"57","author":"S Solapure","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/42.6.735","article-title":"Susceptibility of multidrug-resistant strains of <italic>Mycobacterium tuberculosis<\/italic> to amoxycillin in combination with clavulanic acid and ethambutol","volume":"42","author":"G Abate","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jmii.2015.08.025","article-title":"Anti-<italic>Mycobacterium tuberculosis<\/italic> activity of antituberculosis drugs and amoxicillin\/clavulanate combination","volume":"49","author":"AD Pagliotto","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1128\/AAC.31.8.1204","article-title":"Response of <italic>Streptococcus pyogenes<\/italic> to therapy with amoxicillin or amoxicillin-clavulanic acid in a mouse model of mixed infection caused by <italic>Staphylococcus aureus<\/italic> and <italic>Streptococcus pyogenes<\/italic>","volume":"31","author":"RJ Boon","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"EM Svensson","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824: Novel insights from transcriptional profiling","volume":"2","author":"U Manjunatha","year":"2009","journal-title":"Commun Integr Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present and future","volume":"3","author":"T Mukherjee","year":"2011","journal-title":"Future Med Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e43170","DOI":"10.1371\/journal.pone.0043170","article-title":"Modern lineages of Mycobacterium tuberculosis exhibit lineage-specific patterns of growth and cytokine induction in human monocyte-derived macrophages","volume":"7","author":"R Sarkar","year":"2012","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1128\/IAI.63.9.3428-3437.1995","article-title":"Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice","volume":"63","author":"PL Dunn","year":"1995","journal-title":"Infection and Immunity"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.4049\/jimmunol.162.11.6740","article-title":"<italic>Mycobacterium tuberculosis<\/italic> CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates","volume":"162","author":"C Manca","year":"1999","journal-title":"The Journal of Immunology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.00720-11","article-title":"Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis","volume":"56","author":"MC Rouan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"R Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","unstructured":"Novartis (2002) Lamprene (clofazimine) prescribing information. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2016\/019500s013lblpdf\" xlink:type=\"simple\">https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2016\/019500s013lblpdf<\/ext-link>. East Hanover, NJ."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.115.064527","article-title":"Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo","volume":"43","author":"K Sasahara","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/IDR.S62119","article-title":"Delamanid expanded access novel treatment of drug resistant tuberculosis","volume":"8","author":"R Rustomjee","year":"2015","journal-title":"Infection and Drug Resistance"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"HY Yoon","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5588\/ijtld.14.0335","article-title":"QTc prolongation and treatment of multidrug-resistant tuberculosis","volume":"19","author":"E Harausz","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tig.2012.11.005","article-title":"The heterogeneous evolution of multidrug-resistant <italic>Mycobacterium tuberculosis<\/italic>","volume":"29","author":"B Muller","year":"2013","journal-title":"Trends Genet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"MZ Imperial","year":"2018","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0217670","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0215607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T13:35:22Z","timestamp":1694871322000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0215607"}},"subtitle":[],"editor":[{"given":"Olivier","family":"Neyrolles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0215607","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0217670","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]}}}